Novel breast screening technology increases diagnostic accuracy
The addition of three-dimensional breast imaging—a technology called tomosynthesis—to standard digital mammography significantly increases radiologists' diagnostic accuracy while reducing false positive recall rates, ...
Other
Nov 20, 2012 |
4 / 5 (1) |
0
Researchers excel in predicting cancer drug sensitivity
Researchers from Helsinki Institute for Information Technology HIIT and Institute for Molecular Medicine Finland FIMM have developed a triumphant solution for predicting responses of breast cancer cells to a set of cancer ...
Cancer
Nov 19, 2012 |
5 / 5 (1) |
0
Breast cancer drug geldanamycin could halt other tumors
A drug commonly used in treating breast cancer could have far wider benefits, offering a new way of preventing cancers spreading through the body, according to a University of Leeds-led study.
Cancer
Nov 06, 2012 |
4.8 / 5 (4) |
0
|
Combination treatment may improve survival of breast cancer patients with brain metastases
Adding an angiogenesis inhibitor to treatment with a HER2-inhibiting drug could improve outcomes for patients with HER2-positive breast cancer who develop brain metastases. In their report published online in PNAS Plus, ...
Cancer
Nov 01, 2012 |
not rated yet |
0
George Mason University researchers target breast cancer in three trials
A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.
Cancer
Nov 01, 2012 |
not rated yet |
0
Scientists identify progenitor cells, potential new 'roots' of breast cancer
Scientists have discovered new types of early cells in mammary glands, uncovering clues to the origins of different breast cancers - and potential new drug targets, according to findings published in Breast Ca ...
Cancer
Oct 29, 2012 |
2 / 5 (1) |
0
|
An epigenetic difference in twins explains different risk of breast cancer
Monozygotic twins have the same genome, that is, the same DNA molecule in both siblings. Despite being genetically identical, both twins may have different diseases at different times. This phenomenon is ...
Cancer
Oct 17, 2012 |
not rated yet |
0
Abraxane approved to treat advanced lung cancer
(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung ...
Cancer
Oct 14, 2012 |
not rated yet |
0
HRT taken for 10 years significantly reduces risk of heart failure and heart attack
HRT therapy has been subject to much discussion due to both positive effects (reduced risk of cardiovascular disease) and negative effects (increased risk of breast cancer). A paper published in the BMJ Group's Journal of ...
Cardiology
Oct 09, 2012 |
not rated yet |
0
3-D mammograms offer clearer view of breast cancer
Bringing life-like detail to a hospital near you: the 3-D mammogram, which doctors say is detecting breast cancer earlier and more accurately than traditional tests.
Cancer
Oct 07, 2012 |
not rated yet |
0
Additional medicines can reduce recurrence risk, but come with their own issues
After surgeons removed the tumor from her breast last November, Karen Hajiaskari, of Hamburg, N.Y., was deemed cancer-free. But for the next five years she will take a drug called tamoxifen, a medication that's commonly used ...
Cancer
Oct 07, 2012 |
5 / 5 (2) |
0
Trojan horse drug therapy provides new approach to treating breast cancer
When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.
Cancer
Oct 02, 2012 |
5 / 5 (1) |
0
|
Biological markers increase clinical trial success rate of new breast cancer drugs
Using biological markers—genetic characteristics that are associated with some patients with breast cancer—can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research ...
Cancer
Oct 01, 2012 |
not rated yet |
0
New findings on optimal duration of trastuzumab therapy for women with HER2+ early breast cancer
New studies that advance understanding of the optimal duration of therapy with the targeted cancer drug trastuzumab were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Cancer
Oct 01, 2012 |
not rated yet |
0
Breast cancer recurrence defined by hormone receptor status
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows ...
Cancer
Oct 01, 2012 |
not rated yet |
0
|
